Share on StockTwits

Pacific Biosciences of California (NASDAQ:PACB) Director William W. Ericson purchased 39,299 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was purchased at an average cost of $5.14 per share, with a total value of $201,996.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Pacific Biosciences of California (NASDAQ:PACB) traded up 1.02% during mid-day trading on Thursday, hitting $4.96. 510,510 shares of the company’s stock traded hands. Pacific Biosciences of California has a one year low of $3.32 and a one year high of $8.20. The stock has a 50-day moving average of $5.1 and a 200-day moving average of $5.46. The company’s market cap is $350.3 million.

Pacific Biosciences of California (NASDAQ:PACB) last issued its quarterly earnings data on Thursday, July 24th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.12. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter in the previous year, the company posted ($0.33) earnings per share. The company’s revenue for the quarter was up 90.0% on a year-over-year basis. On average, analysts predict that Pacific Biosciences of California will post $-1.07 earnings per share for the current fiscal year.

Pacific Biosciences, Inc develops Deoxyribonucleic Acid (NASDAQ:PACB) sequencing platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.